Author:
Kim Yong-Jae,Kim Eung-Gyu
Reference35 articles.
1. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet. 2005;366(9493):1267–78.
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002;360(9326):7–22.
3. Hosomi N, Nagai Y, Kohriyama T, Ohtsuki T, Aoki S, Nezu T, et al. The Japan statin treatment against recurrent stroke (J-STARS): a multicenter, randomized, open-label. Parallel-group Study EBio Med. 2015;2(9):1071–8.
4. Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, et al. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial). Circulation. 2017;136(25):2440–50.
5. Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA, et al. Stroke prevention with the PCSK9 (Proprotein convertase Subtilisin-Kexin type 9) inhibitor Evolocumab added to statin in high-Risk patients with stable atherosclerosis. Stroke. 2020;51(5):1546–54.